SRPT ▲ +1.2% - Sarepta Therapeutics, Inc.
$SRPT - Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
30-SEP-2026 08:39 AM ET
Share this post
More filings for $SRPT
SRPT ▲ +0.9% - Sarepta Therapeutics, Inc.Sep 25, 2026SRPT ▼ -0.8% - Sarepta Therapeutics, Inc.Sep 24, 2026SRPT ▼ -0.8% - Sarepta Therapeutics, Inc.Sep 24, 2026SRPT ▼ -13.6% - Sarepta Therapeutics, Inc.Sep 8, 2026SRPT ▲ +10.4% - Sarepta Therapeutics, Inc.Sep 2, 2026SRPT - Sarepta Therapeutics, Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026
View full $SRPT filing history →💬 Comments
Loading comments…
Leave a comment